BME100 s2014:W Group12 L2
|BME 100 Fall 2013|| Home |
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
LAB 2 WRITE-UP
SUMMARY Groups Count Sum Average Variance 0mg 10 38.34 3.834 2.31956 5mg 10 89.32 8.932 2.54061778 10mg 10 616.22 61.622 906.653884 15mg 10 6579.41 657.941 45344.7111
Total 3443322.72 39
T-Tests 0mg-5mg 8.59631E-07 0mg-10mg 9.94377E-06 0mg-15mg 1.39436E-08 5mg-10mg 3.01859E-05 5mg-15mg 1.57101E-08 10mg-15mg 6.4824E-08
New P value 0.008333333
There was significant difference between each collection of data.
There was no significant difference between the data.
After Kristen performed the data collection we were able to conduct a comprehensive statistical data analysis on the data provided. After performing the T-test on the rat data we were able to reasonably conclude that the P value for the data was approximately .867. This means that there is an 87% chance of the data results occurring by chance if the experiment was performed again. After performing the ANOVA test on the human data we were able to reasonably conclude that the P value was 1.40083382702518E-16. This indicates an extremely strong case against the null hypothesis. After the performance of the Bonferroni Correction we were able to confirm that there was a statistically significant difference (P value < 0.05/6) among each comparison of data. By analyzing both tests it can be determined, to a certain extent, that Inflammotin levels rise with an increased dosage of LPS. It is undetermined when this trend would cease based on the available data, so more tests need to be performed in order to accurately determine when this would occur. According to Kristen the Inflammotin levels rose significantly within the rat population which according to our statistical analysis is in fact false. Perhaps Kristen’s mistake resulted from her small sample size and misinterpreting the average values of Inflammotin as being significant. To conclude, we can reasonably determine that by increasing LPS dosage the Inflammotin levels are increased within humans. More tests would have to be performed in order to further validate any conclusions.